HomeGLSHQ • OTCMKTS
add
Gelesis Holdings Inc
Previous close
$0.00
Market cap
70.00 USD
Avg Volume
952.00
P/E ratio
-
Dividend yield
-
Primary exchange
OTCMKTS
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2023info | Y/Y change |
|---|---|---|
Revenue | 1.11M | — |
Operating expense | 10.60M | — |
Net income | -7.68M | — |
Net profit margin | -693.86 | — |
Earnings per share | — | — |
EBITDA | -7.93M | — |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 7.91M | — |
Total assets | 95.88M | — |
Total liabilities | 114.50M | — |
Total equity | -18.62M | — |
Shares outstanding | 73.34M | — |
Price to book | -0.00 | — |
Return on assets | -25.68% | — |
Return on capital | -55.33% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2023info | Y/Y change |
|---|---|---|
Net income | -7.68M | — |
Cash from operations | 617.00K | — |
Cash from investing | -18.00K | — |
Cash from financing | 4.17M | — |
Net change in cash | 4.81M | — |
Free cash flow | 3.82M | — |
About
Gelesis is a biotechnology company located in Boston, Massachusetts that developed the weight loss device Gelesis100 for use in overweight and obesity. The company produces Gelesis100, which is a superabsorbent hydrogel capsule that expands in the stomach, creating a feeling of fullness, helping people reduce the amount of food they eat. The company was founded in 2006 to develop medical devices and treatments for obesity.
Gelesis Holdings, Inc. together with its two affiliates, filed for voluntary Chapter 7 liquidation in the United States Bankruptcy Court for the District of Delaware on October 30, 2023. The debtor listed its assets among the 50 and the $100 million and liabilities of $44.34 million. The Debtor is represented by Kenneth Listwak of Troutman Pepper Hamilton Sanders LLP as counsel. Wikipedia
Founded
2006
Headquarters
Website
Employees
93
